A Study Evaluating Tarceva in Combination With Avastin Versus Avastin Alone in Treating Metastatic Renal Cell Carcinoma
Status:
Completed
Trial end date:
2005-07-01
Target enrollment:
Participant gender:
Summary
The primary purpose of the study is to assess the potential benefit of combining two targeted
therapies (an anti-EGF inhibitor along with an anti-VEGF inhibitor). The goal will be to
determine whether the addition of Erlotinib to Avastin will improve the benefit in metastatic
renal cell carcinoma (RCC) with regard to time to progression, response rate, duration of
response, and survival compared with Avastin alone. Since Avastin has been shown to be active
in renal cancer, the goal will be to assess whether this activity can be enhanced with
Erlotinib.